APO Research
Talk to an analyst

APO RESEARCH · REPORT

Biosimilar Insulin

Biosimilar insulin is a biological copy of an original insulin and there is increasing interest in developing and using them. Biosimilar insulins (hereafter called biosimilars or follow-on biologics) are designed to be highly similar to the original, or reference, insulin product described in a patent. They are analogous to generic versions of small-molecule drugs and are developed by companies other than the reference product's patent holder. Producers of biosimilars use manufacturing techniques that are similar, but likely not identical to, those used by the original patent holder. Thus, although a biosimilar and its reference insulin product will have the same amino acid sequence, they may differ slightly in their more subtle molecular characteristics and clinical profiles.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Biosimilar insulin is a biological copy of an original insulin and there is increasing interest in developing and using them. Biosimilar insulins (hereafter called biosimilars or follow-on biologics) are designed to be highly similar to the original, or reference, insulin product described in a patent. They are analogous to generic versions of small-molecule drugs and are developed by companies other than the reference product's patent holder. Producers of biosimilars use manufacturing techniques that are similar, but likely not identical to, those used by the original patent holder. Thus, although a biosimilar and its reference insulin product will have the same amino acid sequence, they may differ slightly in their more subtle molecular characteristics and clinical profiles.

Selected research

Market Structure

Global Biosimilar Insulin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

29 December 2025188 pages

Choose your research edition.

Industry ResearchBiosimilar Insulin Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Biosimilar Insulin Industry Growth and Trends Forecast to 203294 pages · $3,450 USDMarket StructureGlobal Biosimilar Insulin Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biosimilar Insulin Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Biosimilar Insulin Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

Biosimilar insulin is a biological copy of an original insulin and there is increasing interest in developing and using them. Biosimilar insulins (hereafter called biosimilars or follow-on biologics) are designed to be highly similar to the original, or reference, insulin product described in a patent. They are analogous to generic versions of small-molecule drugs and are developed by companies other than the reference product's patent holder. Producers of biosimilars use manufacturing techniques that are similar, but likely not identical to, those used by the original patent holder. Thus, although a biosimilar and its reference insulin product will have the same amino acid sequence, they may differ slightly in their more subtle molecular characteristics and clinical profiles.

Global Biosimilar Insulin key players include Biocon, Gan&Lee, Wockhardt, Eli Lilly, Sanofi etc. Global top three players hold a share over 70%. India is the largest market, with a share about 30%, followed by Southeast Asia and China, both have a share about 40 percent

This report provides an overview of the global Biosimilar Insulin market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of Biosimilar Insulin and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Biosimilar Insulin sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Biosimilar Insulin market size, projected growth trends, production technologies, key applications, and end-use industries.

Biosimilar Insulin Segment by Company

Eli Lilly

Sanofi

Gan&Lee

Tonghua Dongbao

United Laboratory

Geropharm

Biocon

Wockhardt

Biosimilar Insulin Segment by Type

Biosimilar Insulin Glargine

Biosimilar Insulin Lispro

Other

Biosimilar Insulin Segment by Distribution Channel

Hospital

Retail Pharmacy

Others

Biosimilar Insulin Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilar Insulin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biosimilar Insulin and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilar Insulin.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Biosimilar Insulin market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Biosimilar Insulin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Biosimilar Insulin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Biosimilar Insulin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Biosimilar Insulin Industry Trends Table 2. Biosimilar Insulin Industry Drivers Table 3. Biosimilar Insulin Industry Opportunities and Challenges Table 4. Biosimilar Insulin Industry Restraints Table 5. Global Biosimilar Insulin Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Biosimilar Insulin Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Biosimilar Insulin Sales by Manufacturers (K Unit) & (2021-2026) Table 8. Global Biosimilar Insulin Sales Market Share by Manufacturers Table 9. Global Biosimilar Insulin Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Biosimilar Insulin Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Biosimilar Insulin Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Biosimilar Insulin Manufacturers, Product Type & Application Table 13. Global Biosimilar Insulin Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Biosimilar Insulin by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Biosimilar Insulin Glargine Table 17. Major Manufacturers of Biosimilar Insulin Lispro Table 18. Major Manufacturers of Other Table 19. Global Biosimilar Insulin Sales by Type 2021 VS 2025 VS 2032 (K Unit) Table 20. Global Biosimilar Insulin Sales by Type (2021-2026) & (K Unit) Table 21. Global Biosimilar Insulin Sales by Type (2027-2032) & (K Unit) Table 22. Global Biosimilar Insulin Sales Market Share by Type (2021-2026) Table 23. Global Biosimilar Insulin Sales Market Share by Type (2027-2032) Table 24. Global Biosimilar Insulin Revenue by Type 2021 VS 2025 VS 2032 (K Unit) Table 25. Global Biosimilar Insulin Revenue by Type (2021-2026) & (K Unit) Table 26. Global Biosimilar Insulin Revenue by Type (2027-2032) & (K Unit) Table 27. Global Biosimilar Insulin Revenue Market Share by Type (2021-2026) Table 28. Global Biosimilar Insulin Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Hospital Table 30. Major Manufacturers of Retail Pharmacy Table 31. Major Manufacturers of Others Table 32. Global Biosimilar Insulin Sales by Application 2021 VS 2025 VS 2032 (K Unit) Table 33. Global Biosimilar Insulin Sales by Application (2021-2026) & (K Unit) Table 34. Global Biosimilar Insulin Sales by Application (2027-2032) & (K Unit) Table 35. Global Biosimilar Insulin Sales Market Share by Application (2021-2026) Table 36. Global Biosimilar Insulin Sales Market Share by Application (2027-2032) Table 37. Global Biosimilar Insulin Revenue by Application 2021 VS 2025 VS 2032 (K Unit) Table 38. Global Biosimilar Insulin Revenue by Application (2021-2026) & (K Unit) Table 39. Global Biosimilar Insulin Revenue by Application (2027-2032) & (K Unit) Table 40. Global Biosimilar Insulin Revenue Market Share by Application (2021-2026) Table 41. Global Biosimilar Insulin Revenue Market Share by Application (2027-2032) Table 42. Global Biosimilar Insulin Sales by Region: 2021 VS 2025 VS 2032 (K Unit) Table 43. Global Biosimilar Insulin Sales by Region (2021-2026) & (K Unit) Table 44. Global Biosimilar Insulin Sales Market Share by Region (2021-2026) Table 45. Global Biosimilar Insulin Sales Forecasted by Region (2027-2032) & (K Unit) Table 46. Global Biosimilar Insulin Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Biosimilar Insulin Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Unit) Table 48. North America Biosimilar Insulin Sales by Country (2021-2026) & (K Unit) Table 49. North America Biosimilar Insulin Sales by Country (2027-2032) & (K Unit) Table 50. Europe Biosimilar Insulin Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Unit) Table 51. Europe Biosimilar Insulin Sales by Country (2021-2026) & (K Unit) Table 52. Europe Biosimilar Insulin Sales by Country (2027-2032) & (K Unit) Table 53. Asia Pacific Biosimilar Insulin Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Unit) Table 54. Asia Pacific Biosimilar Insulin Sales by Country (2021-2026) & (K Unit) Table 55. Asia Pacific Biosimilar Insulin Sales by Country (2027-2032) & (K Unit) Table 56. South America, Middle East and Africa Biosimilar Insulin Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Unit) Table 57. South America, Middle East and Africa Biosimilar Insulin Sales by Country (2021-2026) & (K Unit) Table 58. South America, Middle East and Africa Biosimilar Insulin Sales by Country (2027-2032) & (K Unit) Table 59. Global Biosimilar Insulin Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Biosimilar Insulin Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Biosimilar Insulin Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Biosimilar Insulin Revenue Market Share by Region (2021-2026) Table 63. Global Biosimilar Insulin Revenue Market Share by Region (2027-2032) Table 64. Eli Lilly Company Information Table 65. Eli Lilly Business Overview Table 66. Eli Lilly Biosimilar Insulin Sales (K Unit), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Eli Lilly Biosimilar Insulin Product Portfolio Table 68. Eli Lilly Recent Development Table 69. Sanofi Company Information Table 70. Sanofi Business Overview Table 71. Sanofi Biosimilar Insulin Sales (K Unit), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Sanofi Biosimilar Insulin Product Portfolio Table 73. Sanofi Recent Development Table 74. Gan&Lee Company Information Table 75. Gan&Lee Business Overview Table 76. Gan&Lee Biosimilar Insulin Sales (K Unit), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Gan&Lee Biosimilar Insulin Product Portfolio Table 78. Gan&Lee Recent Development Table 79. Tonghua Dongbao Company Information Table 80. Tonghua Dongbao Business Overview Table 81. Tonghua Dongbao Biosimilar Insulin Sales (K Unit), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Tonghua Dongbao Biosimilar Insulin Product Portfolio Table 83. Tonghua Dongbao Recent Development Table 84. United Laboratory Company Information Table 85. United Laboratory Business Overview Table 86. United Laboratory Biosimilar Insulin Sales (K Unit), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. United Laboratory Biosimilar Insulin Product Portfolio Table 88. United Laboratory Recent Development Table 89. Geropharm Company Information Table 90. Geropharm Business Overview Table 91. Geropharm Biosimilar Insulin Sales (K Unit), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Geropharm Biosimilar Insulin Product Portfolio Table 93. Geropharm Recent Development Table 94. Biocon Company Information Table 95. Biocon Business Overview Table 96. Biocon Biosimilar Insulin Sales (K Unit), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Biocon Biosimilar Insulin Product Portfolio Table 98. Biocon Recent Development Table 99. Wockhardt Company Information Table 100. Wockhardt Business Overview Table 101. Wockhardt Biosimilar Insulin Sales (K Unit), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Wockhardt Biosimilar Insulin Product Portfolio Table 103. Wockhardt Recent Development Table 104. Key Raw Materials Table 105. Raw Materials Key Suppliers Table 106. Biosimilar Insulin Distributors List Table 107. Biosimilar Insulin Customers List Table 108. Research Programs/Design for This Report Table 109. Authors List of This Report Table 110. Secondary Sources Table 111. Primary Sources List of Figures Figure 1. Biosimilar Insulin Product Image Figure 2. Global Biosimilar Insulin Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Biosimilar Insulin Market Size (2021-2032) & (US$ Million) Figure 4. Global Biosimilar Insulin Sales (2021-2032) & (K Unit) Figure 5. Global Biosimilar Insulin Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Biosimilar Insulin Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Biosimilar Insulin Glargine Image Figure 9. Biosimilar Insulin Lispro Image Figure 10. Other Image Figure 11. Global Biosimilar Insulin Sales by Type (2021 VS 2025 VS 2032) & (K Unit) Figure 12. Global Biosimilar Insulin Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global Biosimilar Insulin Sales Market Share by Type (2021-2032) Figure 14. Global Biosimilar Insulin Revenue by Type (2021 VS 2025 VS 2032) & (K Unit) Figure 15. Global Biosimilar Insulin Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global Biosimilar Insulin Revenue Market Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Retail Pharmacy Image Figure 19. Others Image Figure 20. Global Biosimilar Insulin Sales by Application (2021 VS 2025 VS 2032) & (K Unit) Figure 21. Global Biosimilar Insulin Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Biosimilar Insulin Sales Market Share by Application (2021-2032) Figure 23. Global Biosimilar Insulin Revenue by Application (2021 VS 2025 VS 2032) & (K Unit) Figure 24. Global Biosimilar Insulin Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Biosimilar Insulin Revenue Market Share by Application (2021-2032) Figure 26. North America Biosimilar Insulin Sales and Growth Rate (2021-2032) & (K Unit) Figure 27. North America Biosimilar Insulin Sales Market Share by Country (2021-2032) Figure 28. U.S. Biosimilar Insulin Sales and Growth Rate (2021-2032) & (K Unit) Figure 29. Canada Biosimilar Insulin Sales and Growth Rate (2021-2032) & (K Unit) Figure 30. Mexico Biosimilar Insulin Sales and Growth Rate (2021-2032) & (K Unit) Figure 31. Europe Biosimilar Insulin Sales and Growth Rate (2021-2032) & (K Unit) Figure 32. Europe Biosimilar Insulin Sales Market Share by Country (2021-2032) Figure 33. Germany Biosimilar Insulin Sales and Growth Rate (2021-2032) & (K Unit) Figure 34. France Biosimilar Insulin Sales and Growth Rate (2021-2032) & (K Unit) Figure 35. U.K. Biosimilar Insulin Sales and Growth Rate (2021-2032) & (K Unit) Figure 36. Italy Biosimilar Insulin Sales and Growth Rate (2021-2032) & (K Unit) Figure 37. Netherlands Biosimilar Insulin Sales and Growth Rate (2021-2032) & (K Unit) Figure 38. Asia Pacific Biosimilar Insulin Sales and Growth Rate (2021-2032) & (K Unit) Figure 39. Asia Pacific Biosimilar Insulin Sales Market Share by Country (2021-2032) Figure 40. China Biosimilar Insulin Sales and Growth Rate (2021-2032) & (K Unit) Figure 41. Japan Biosimilar Insulin Sales and Growth Rate (2021-2032) & (K Unit) Figure 42. South Korea Biosimilar Insulin Sales and Growth Rate (2021-2032) & (K Unit) Figure 43. Southeast Asia Biosimilar Insulin Sales and Growth Rate (2021-2032) & (K Unit) Figure 44. India Biosimilar Insulin Sales and Growth Rate (2021-2032) & (K Unit) Figure 45. Australia Biosimilar Insulin Sales and Growth Rate (2021-2032) & (K Unit) Figure 46. South America, Middle East and Africa Biosimilar Insulin Sales and Growth Rate (2021-2032) & (K Unit) Figure 47. South America, Middle East and Africa Biosimilar Insulin Sales Market Share by Country (2021-2032) Figure 48. Brazil Biosimilar Insulin Sales and Growth Rate (2021-2032) & (K Unit) Figure 49. South Africa Biosimilar Insulin Sales and Growth Rate (2021-2032) & (K Unit) Figure 50. Saudi Arabia Biosimilar Insulin Sales and Growth Rate (2021-2032) & (K Unit) Figure 51. Turkey Biosimilar Insulin Sales and Growth Rate (2021-2032) & (K Unit) Figure 52. Argentina Biosimilar Insulin Sales and Growth Rate (2021-2032) & (K Unit) Figure 53. UAE Biosimilar Insulin Sales and Growth Rate (2021-2032) & (K Unit) Figure 54. Egypt Biosimilar Insulin Sales and Growth Rate (2021-2032) & (K Unit) Figure 55. Chile Biosimilar Insulin Sales and Growth Rate (2021-2032) & (K Unit) Figure 56. Global Biosimilar Insulin Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Biosimilar Insulin Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Biosimilar Insulin Revenue (2021-2032) & (US$ Million) Figure 59. North America Biosimilar Insulin Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Biosimilar Insulin Revenue (2021-2032) & (US$ Million) Figure 61. Europe Biosimilar Insulin Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Biosimilar Insulin Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Biosimilar Insulin Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Biosimilar Insulin Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Biosimilar Insulin Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Biosimilar Insulin Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Biosimilar Insulin Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Biosimilar Insulin Glargine
  • Biosimilar Insulin Lispro
  • Other
Applications
  • Hospital
  • Retail Pharmacy
  • Others
Companies covered
  • Eli Lilly
  • Sanofi
  • Gan&Lee
  • Tonghua Dongbao
  • United Laboratory
  • Geropharm
  • Biocon
  • Wockhardt

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Biosimilar Insulin Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Biosimilar Insulin Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Biosimilar Insulin Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Biosimilar Insulin Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Biosimilar Insulin Market Dynamics
  1. 2.1 Biosimilar Insulin Industry Trends
  2. 2.2 Biosimilar Insulin Industry Drivers
  3. 2.3 Biosimilar Insulin Industry Opportunities and Challenges
  4. 2.4 Biosimilar Insulin Industry Restraints
3 Biosimilar Insulin Market by Manufacturers
  1. 3.1 Global Biosimilar Insulin Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Biosimilar Insulin Sales by Manufacturers (2021-2026)
  3. 3.3 Global Biosimilar Insulin Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Biosimilar Insulin Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Biosimilar Insulin Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Biosimilar Insulin Manufacturers, Product Type & Application
  7. 3.7 Global Biosimilar Insulin Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Biosimilar Insulin Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Biosimilar Insulin Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Biosimilar Insulin Tier 1, Tier 2, and Tier 3
4 Biosimilar Insulin Market by Type
  1. 4.1 Biosimilar Insulin Type Introduction
  2. 4.1.1 Biosimilar Insulin Glargine
  3. 4.1.2 Biosimilar Insulin Lispro
  4. 4.1.3 Other
  5. 4.2 Global Biosimilar Insulin Sales by Type
  6. 4.2.1 Global Biosimilar Insulin Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Biosimilar Insulin Sales by Type (2021-2032)
  8. 4.2.3 Global Biosimilar Insulin Sales Market Share by Type (2021-2032)
  9. 4.3 Global Biosimilar Insulin Revenue by Type
  10. 4.3.1 Global Biosimilar Insulin Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Biosimilar Insulin Revenue by Type (2021-2032)
  12. 4.3.3 Global Biosimilar Insulin Revenue Market Share by Type (2021-2032)
5 Biosimilar Insulin Market by Application
  1. 5.1 Biosimilar Insulin Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Retail Pharmacy
  4. 5.1.3 Others
  5. 5.2 Global Biosimilar Insulin Sales by Application
  6. 5.2.1 Global Biosimilar Insulin Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Biosimilar Insulin Sales by Application (2021-2032)
  8. 5.2.3 Global Biosimilar Insulin Sales Market Share by Application (2021-2032)
  9. 5.3 Global Biosimilar Insulin Revenue by Application
  10. 5.3.1 Global Biosimilar Insulin Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Biosimilar Insulin Revenue by Application (2021-2032)
  12. 5.3.3 Global Biosimilar Insulin Revenue Market Share by Application (2021-2032)
6 Global Biosimilar Insulin Sales by Region
  1. 6.1 Global Biosimilar Insulin Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Biosimilar Insulin Sales by Region (2021-2032)
  3. 6.2.1 Global Biosimilar Insulin Sales by Region (2021-2026)
  4. 6.2.2 Global Biosimilar Insulin Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Biosimilar Insulin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Biosimilar Insulin Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Biosimilar Insulin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Biosimilar Insulin Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Biosimilar Insulin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Biosimilar Insulin Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Biosimilar Insulin Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Biosimilar Insulin Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Biosimilar Insulin Revenue by Region
  1. 7.1 Global Biosimilar Insulin Revenue by Region
  2. 7.1.1 Global Biosimilar Insulin Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Biosimilar Insulin Revenue by Region (2021-2026)
  4. 7.1.3 Global Biosimilar Insulin Revenue by Region (2027-2032)
  5. 7.1.4 Global Biosimilar Insulin Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Biosimilar Insulin Revenue (2021-2032)
  8. 7.2.2 North America Biosimilar Insulin Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Biosimilar Insulin Revenue (2021-2032)
  11. 7.3.2 Europe Biosimilar Insulin Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Biosimilar Insulin Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Biosimilar Insulin Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Biosimilar Insulin Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Biosimilar Insulin Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Eli Lilly
  2. 8.1.1 Eli Lilly Company Information
  3. 8.1.2 Eli Lilly Business Overview
  4. 8.1.3 Eli Lilly Biosimilar Insulin Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Eli Lilly Biosimilar Insulin Product Portfolio
  6. 8.1.5 Eli Lilly Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Biosimilar Insulin Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Biosimilar Insulin Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Gan&Lee
  14. 8.3.1 Gan&Lee Company Information
  15. 8.3.2 Gan&Lee Business Overview
  16. 8.3.3 Gan&Lee Biosimilar Insulin Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Gan&Lee Biosimilar Insulin Product Portfolio
  18. 8.3.5 Gan&Lee Recent Developments
  19. 8.4 Tonghua Dongbao
  20. 8.4.1 Tonghua Dongbao Company Information
  21. 8.4.2 Tonghua Dongbao Business Overview
  22. 8.4.3 Tonghua Dongbao Biosimilar Insulin Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Tonghua Dongbao Biosimilar Insulin Product Portfolio
  24. 8.4.5 Tonghua Dongbao Recent Developments
  25. 8.5 United Laboratory
  26. 8.5.1 United Laboratory Company Information
  27. 8.5.2 United Laboratory Business Overview
  28. 8.5.3 United Laboratory Biosimilar Insulin Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 United Laboratory Biosimilar Insulin Product Portfolio
  30. 8.5.5 United Laboratory Recent Developments
  31. 8.6 Geropharm
  32. 8.6.1 Geropharm Company Information
  33. 8.6.2 Geropharm Business Overview
  34. 8.6.3 Geropharm Biosimilar Insulin Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Geropharm Biosimilar Insulin Product Portfolio
  36. 8.6.5 Geropharm Recent Developments
  37. 8.7 Biocon
  38. 8.7.1 Biocon Company Information
  39. 8.7.2 Biocon Business Overview
  40. 8.7.3 Biocon Biosimilar Insulin Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Biocon Biosimilar Insulin Product Portfolio
  42. 8.7.5 Biocon Recent Developments
  43. 8.8 Wockhardt
  44. 8.8.1 Wockhardt Company Information
  45. 8.8.2 Wockhardt Business Overview
  46. 8.8.3 Wockhardt Biosimilar Insulin Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Wockhardt Biosimilar Insulin Product Portfolio
  48. 8.8.5 Wockhardt Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Biosimilar Insulin Value Chain Analysis
  2. 9.1.1 Biosimilar Insulin Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Biosimilar Insulin Production Mode & Process
  6. 9.2 Biosimilar Insulin Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Biosimilar Insulin Distributors
  9. 9.2.3 Biosimilar Insulin Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst